(2008)
Exemplaires (1)
Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Exemplaires (1)
|
| TU 004870 | TU 4.7.2. DEA D | Monographie | Bibliothèque FARES | Tuberculose | Consultation sur place
Exclu du prêt |
Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Aucun avis, veuillez vous identifier pour ajouter le vôtre !
| Titre : |
Effectiveness and safety of meropenem / clavulanate-containing regimens in the treatment of MDR- and XDR-TB |
| Type de document : |
document électronique |
| Auteurs : |
Simon Tiberi, Auteur ; Marie-Christine Payen, Auteur ; Giovanni Sotgiu, Auteur |
| Editeur : |
European Respiratory Society (ERS) |
| Année de publication : |
2016 |
| Collection : |
European Respiratory Journal num. vol.47 nr 4 |
| Importance : |
p.1235-1243 |
| Langues : |
Anglais (eng) |
| Catégories : |
[TUBER] étude
[TUBER] traitement:résistance
|
| Index. décimale : |
TU 8.5.1. MDR (Multi Drug Resistance / XDR (X-treme Drug Resistance) |
| Résumé : |
No large study has ever evaluated the efficacy, safety and tolerability of meropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/clavulanate added to a background regimen when treating MDR- and XDR-TB cases.
Patients treated with a meropenem/clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p<0.0001) and the median (interquartile range (IQR)) number of antibiotic resistances was higher (8 (6–9) versus 5 (4–6)). Patients were treated with a meropenem/clavulanate-containing regimen for a median (IQR) of 85 (49–156) days.
No statistically significant differences were observed in the overall MDR-TB cohort and in the subgroups with and without the XDR-TB patients; in particular, sputum smear and culture conversion rates were similar in XDR-TB patients exposed to meropenem/clavulanate-containing regimens (88.0% versus 100.0%, p=1.00 and 88.0% versus 100.0%, p=1.00, respectively). Only six cases reported adverse events attributable to meropenem/clavulanate (four of them then restarting treatment).
The nondifferent outcomes and bacteriological conversion rate observed in cases who were more severe than controls might imply that meropenem/clavulanate could be active in treating MDR- and XDR-TB cases. |
| En ligne : |
https://doi.org/10.1183/13993003.02146-2015 |
| Format de la ressource électronique : |
Article en ligne |
| Permalink : |
https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10150 |
|
Aucun avis, veuillez vous identifier pour ajouter le vôtre !
| Titre : |
Genome-wide association studies of global Mycobacterium tuberculosis resistance to 13 antimicrobials in 10,228 genomes identify new resistance mechanisms |
| Type de document : |
document électronique |
| Auteurs : |
The CRyPTIC Consortium (University of Oxford, Oxford, Royaume-Uni), Auteur |
| Editeur : |
Public Library of Science (PLOS) |
| Année de publication : |
2022 |
| Collection : |
PLOS Biology, ISSN 1545-7885 |
| Langues : |
Anglais (eng) |
| Catégories : |
[TUBER] étude:épidémiologie:génétique
[TUBER] traitement:résistance
|
| Index. décimale : |
TU 3.2. MDR (Multi Drug Resistance) / XDR (X-treme Drug Resistance) |
| Résumé : |
The emergence of drug-resistant tuberculosis is a major global public health concern that threatens the ability to control the disease. Whole-genome sequencing as a tool to rapidly diagnose resistant infections can transform patient treatment and clinical practice. While resistance mechanisms are well understood for some drugs, there are likely many mechanisms yet to be uncovered, particularly for new and repurposed drugs. We sequenced 10,228 Mycobacterium tuberculosis (MTB) isolates worldwide and determined the minimum inhibitory concentration (MIC) on a grid of 2-fold concentration dilutions for 13 antimicrobials using quantitative microtiter plate assays. We performed oligopeptide- and oligonucleotide-based genome-wide association studies using linear mixed models to discover resistance-conferring mechanisms not currently catalogued. Use of MIC over binary resistance phenotypes increased sample heritability for the new and repurposed drugs by 26% to 37%, increasing our ability to detect novel associations. For all drugs, we discovered uncatalogued variants associated with MIC, including in the Rv1218c promoter binding site of the transcriptional repressor Rv1219c (isoniazid), upstream of the vapBC20 operon that cleaves 23S rRNA (linezolid) and in the region encoding an α-helix lining the active site of Cyp142 (clofazimine, all p < 10−7.7). We observed that artefactual signals of cross-resistance could be unravelled based on the relative effect size on MIC. Our study demonstrates the ability of very large-scale studies to substantially improve our knowledge of genetic variants associated with antimicrobial resistance in M. tuberculosis. |
| En ligne : |
https://doi.org/10.1371/journal.pbio.3001755 |
| Format de la ressource électronique : |
Article en ligne |
| Permalink : |
https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9919 |
|
Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Exemplaires (1)
Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Exemplaires (1)
Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Aucun avis, veuillez vous identifier pour ajouter le vôtre !
| Titre : |
Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis |
| Type de document : |
document électronique |
| Auteurs : |
Sander P. van Rijn, Auteur ; Richard van Altena, Auteur ; Onno W. Akkerman, Auteur |
| Editeur : |
European Respiratory Society (ERS) |
| Année de publication : |
2016 |
| Collection : |
European Respiratory Journal num. vol.47 nr 4 |
| Importance : |
p. 1229-1234 |
| Présentation : |
graph. |
| Langues : |
Anglais (eng) |
| Catégories : |
[TUBER] étude
[TUBER] traitement:résistance
|
| Index. décimale : |
TU 8.5.1. MDR (Multi Drug Resistance / XDR (X-treme Drug Resistance) |
| Résumé : |
Treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) is becoming more challenging because of increased levels of drug resistance against second-line TB drugs. One promising group of antimicrobial drugs is carbapenems. Ertapenem is an attractive carbapenem for the treatment of MDR- and XDR-TB because its relatively long half-life enables once-daily dosing.
A retrospective study was performed for all patients with suspected MDR-TB at the Tuberculosis Center Beatrixoord of the University Medical Center Groningen (Haren, the Netherlands) who received ertapenem as part of their treatment regimen between December 1, 2010 and March 1, 2013. Safety and pharmacokinetics were evaluated.
18 patients were treated with 1000 mg ertapenem for a mean (range) of 77 (5–210) days. Sputum smear and culture were converted in all patients. Drug exposure was evaluated in 12 patients. The mean (range) area under the concentration–time curve up to 24 h was 544.9 (309–1130) h·mg·L−1. The mean (range) maximum observed plasma concentration was 127.5 (73.9–277.9) mg·L−1.
In general, ertapenem treatment was well tolerated during MDR-TB treatment and showed a favourable pharmacokinetic/pharmacodynamic profile in MDR-TB patients. We conclude that ertapenem is a highly promising drug for the treatment of MDR-TB that warrants further investigation. |
| En ligne : |
https://www.doi.org/10.1183/13993003.01654-2015 |
| Format de la ressource électronique : |
Article en ligne |
| Permalink : |
https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10149 |
|
Aucun avis, veuillez vous identifier pour ajouter le vôtre !
| Titre : |
Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones : results from a multicountry surveillance project |
| Type de document : |
document électronique |
| Auteurs : |
Matteo Zignol, Auteur ; Anna Dean, Auteur ; Natavan Alikhanova, Auteur |
| Editeur : |
Lancet |
| Année de publication : |
2016 |
| Collection : |
The Lancet Infectious diseases, ISSN 1473-3099 num. 16(10) |
| Importance : |
p. 1185–1192 |
| Langues : |
Anglais (eng) |
| Catégories : |
[DIVERS] géographie:Afrique:Afrique subsaharienne:Afrique du Sud
[DIVERS] géographie:Europe:Europe centrale et orientale
[TUBER] traitement:résistance
[TUBER] traitement:traitement curatif
[PROMOSAN] étude:enquête
|
| Index. décimale : |
TU 8.2. Traitement curatif |
| Résumé : |
Background
Pyrazinamide and fluoroquinolones are essential antituberculosis drugs in new rifampicin-sparing regimens. However, little information about the extent of resistance to these drugs at the population level is available.
Methods
In a molecular epidemiology analysis, we used population-based surveys from Azerbaijan, Bangladesh, Belarus, Pakistan, and South Africa to investigate resistance to pyrazinamide and fluoroquinolones among patients with tuberculosis. Resistance to pyrazinamide was assessed by gene sequencing with the detection of resistance-conferring mutations in the pncA gene, and susceptibility testing to fluoroquinolones was conducted using the MGIT system.
Findings
Pyrazinamide resistance was assessed in 4972 patients. Levels of resistance varied substantially in the surveyed settings (3·0–42·1%). In all settings, pyrazinamide resistance was significantly associated with rifampicin resistance. Among 5015 patients who underwent susceptibility testing to fluoroquinolones, proportions of resistance ranged from 1·0–16·6% for ofloxacin, to 0·5–12·4% for levofloxacin, and 0·9–14·6% for moxifloxacin when tested at 0·5 μg/mL. High levels of ofloxacin resistance were detected in Pakistan. Resistance to moxifloxacin and gatifloxacin
when tested at 2 μg/mL was low in all countries.
Interpretation
Although pyrazinamide resistance was significantly associated with rifampicin resistance, this drug may still be effective in 19–63% of patients with rifampicin-resistant tuberculosis. Even though the high level of resistance to ofloxacin found in Pakistan is worrisome because it might be the expression of extensive and unregulated use of fluoroquinolones in some parts of Asia, the negligible levels of resistance to fourth-generation fluoroquinolones documented in all survey sites is an encouraging finding. Rational use of this class of antibiotics should therefore be ensured to preserve its effectiveness. |
| En ligne : |
https://doi.org/10.1016/S1473-3099(16)30190-6 |
| Format de la ressource électronique : |
Article en ligne |
| Permalink : |
https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10783 |
|
Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Exemplaires (1)
Aucun avis, veuillez vous identifier pour ajouter le vôtre !
| Titre : |
Tuberculosis |
| Type de document : |
document électronique |
| Auteurs : |
Madhukar Pai, Auteur ; Marcel A. Behr, Auteur ; David W. Dowdy, Auteur |
| Editeur : |
Springer Nature |
| Année de publication : |
2016 |
| Collection : |
Nature Reviews Diseases Primers, ISSN 2056-676X num. 2 (16076)  |
| Importance : |
24 p. |
| Présentation : |
ill. ; tab. |
| Langues : |
Anglais (eng) |
| Catégories : |
[TUBER] dépistage
[TUBER] étude:épidémiologie
[TUBER] prévention
[TUBER] traitement:résistance
[TUBER] traitement:traitement préventif:vaccin BCG
[TUBER] type de tuberculose:infection tuberculeuse
[TUBER] type de tuberculose:tuberculose-maladie
|
| Résumé : |
Tuberculosis (TB) is an airborne infectious disease caused by organisms of the Mycobacterium tuberculosis complex. Although primarily a pulmonary pathogen, M. tuberculosis can cause disease in almost any part of the body. Infection with M. tuberculosis can evolve from containment in the host, in which the bacteria are isolated within granulomas (latent TB infection), to a contagious state, in which the patient will show symptoms that can include cough, fever, night sweats and weight loss. Only active pulmonary TB is contagious. In many low-income and middle-income countries, TB continues to be a major cause of morbidity and mortality, and drug-resistant TB is a major concern in many settings. Although several new TB diagnostics have been developed, including rapid molecular tests, there is a need for simpler point‑of‑care tests. Treatment usually requires a prolonged course of multiple antimicrobials, stimulating efforts to develop shorter drug regimens. Although the Bacillus Calmette–Guérin (BCG) vaccine is used worldwide, mainly to prevent life-threatening TB in infants and young children, it has been ineffective in controlling the global TB epidemic. Thus, efforts are underway to develop newer vaccines with improved efficacy. New tools as well as improved programme implementation and financing are necessary to end the global TB epidemic by 2035.évolu |
| En ligne : |
https://doi.org/10.1038/nrdp.2016.76 |
| Format de la ressource électronique : |
Article en ligne |
| Permalink : |
https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10860 |
|
Aucun avis, veuillez vous identifier pour ajouter le vôtre !
(2003)
Exemplaires (1)
Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Ajouter le résultat dans votre panier Affiner la rechercheDrug-resistant tuberculosis / Curry International Tuberculosis Center and California Department of Public Health (Californie, San Francisco, USA) (2016)
Les origines de la multi-résistance dévoilées / Luc Ruidant in Le journal du médecin, 2396 (27 février 2015)
